Kerex is working the "non-dialysis side(hyperphosphatemia) no dialysis involved and RMTI is dealing with the problem of iron removal by the dialysis process. SPF is a phosphorus/iron compound to help prevent hemoglobin loss.
*ICPT rose from $70 to $275 overnight, then over $400 based on meeting its Phase 2 primary end point and ending the trial early.
*ICPT is estimated to have $3 to $4 billion Annual Peak Sales
*ICPT right now has zero competition for its specific drug
*RMTI has met its primary endpoints in Phase 3 studies
*RMTI is looking to reduce the need for Amgen's EPOGEN which had nearly $2 Billion in sales in 2012
*RMTI must compete with EPOGEN through 2018 as Davita has a service contract to supply EPOGEN until then (90% of sales must come from EPOGEN)
*RMTI has clear sales channels with the largest providers ( Davita & Frensius) as well as several others accounts for over 75% of the market
With existing supply contracts in place RMTI could see annual peak sales of well over $500 million (Calcitrol, Triferic, existing product lines) putting a PT of $50 per share on RMTI
Once supply agreements end for Amgens EPOGEN in a few years the market potial of EPOGEN at $2 billion opens up the possibility of a much higher price target. Do the math. Good luck & Happy traading.